The 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, saw many researchers reporting their most recent clinical trial data. Here, Hareth Nahi, MD, of the Karolinska Institutet, Stockholm, Sweden, gives an overview of the current studies being carried out by the Nordic Myeloma Study Group. These studies include: combination therapy with carfilzomib, cyclophosphamide and dexamethasone in relapsed multiple myeloma (MM); combination therapy with ixazomib, lenalidomide and dexamethasone in newly diagnosed MM; and the role of PET-CT scanning in MM. Finally, Dr Nahi discusses the potential for collaboration across different study groups, as facilitated by large organizations like EHA.
An update from the Nordic Myeloma Study Group
